Pharmaceutical Pipeline
Yale is committed to advancing healthcare through groundbreaking technologies and discoveries. Explore a diverse array of pioneering projects that span the entire drug development process, from early-stage research to clinical trials. With a focus on addressing critical medical challenges, Yale's Pharmaceutical Pipeline showcases the collective expertise and dedication of our researchers who are aiming to bring tangible solutions to market for patients worldwide.
Device Diagnostic
Preclinical
RIG-101
- RIGImmune
- Oncology
Troxatyl
- Beijing HebaBiz
Mucosal covid vaccine
- Xanadu Bio
EGFR-Her2 vaccine
- Therajan
Phase I
PTX-100
- Prescient
BHV-1300
Molecular Degraders of Extracellular Proteins (“MoDE™”) are bispecific molecules that target pathologic circulating proteins and direct them to the liver (or other organ systems) for degradation by the endosomal/lysosomal pathway---a novel, competitive platform with a differentiated profile relative to FcRN inhibitors. Specifically, high circulating levels of antibodies (monoclonal or polyclonal gammopathy) drive conditions such as myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, pemphigus vulgaris, and many other diseases.
- Discovery Platform
- Inflammatory
- Therapeutics
HLD-0915
- Halda Therapeutics
BCSZ110
- Dynamicure
Phase II
ARV-110
- Arvinas
Prostate Cancer
- Oncology
Phase III
ARV-471
- Arvinas
- Breast Cancer
INZ-701 - ENPPI Deficiency
Our lead candidate, INZ-701, is in clinical development for the potential treatment of ENPP1 Deficiency and ABCC6 Deficiency, which are driven by low levels of inorganic pyrophosphate (PPi) andadenosine. Currently, there are no therapeutic options for patients suffering from ENPP1 Deficiency and ABCC6 Deficiency – two rare disorders. We are pioneering the development of effective therapies for these patients and their families.